Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
D-lactate dehydrogenase, mitochondrial (LDHD) is a mitochondrial enzyme and flavoprotein that catalyzes the oxidation of D-lactate to pyruvate and plays a critical role in the catabolism of D-lactate and other D-2-hydroxyacids with hydrophobic moieties[1]. LDHD activity depends on FAD and Mn2+, and it is highly specific for D-enantiomers, with no activity towards L-lactate. Mutations in LDHD are associated with D-lactic acidosis—a rare disorder caused by excessive accumulation of D-lactate. The LDHD enzyme is structurally distinct from classical L-lactate dehydrogenases, possessing an FAD-binding domain, substrate-binding domain, and small C-terminal domain. Loss-of-function mutations in LDHD affect substrate binding and catalysis, which may underlie pathogenic metabolic phenotypes[1][2]. No clinically approved drugs directly target LDHD; however, its disease role suggests possible relevance in metabolic disorders.
Oxidation of D-lactate (and other D-2-hydroxyacids with hydrophobic moieties) to pyruvate via a FAD and Mn2+-dependent catalytic mechanism[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on D-lactate dehydrogenase, mitochondrial (LDHD).